louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06741839: Confocal Laser Endomicroscopy Guided Medical Thoracoscopy for the Diagnosis of Pleural Disease
Official title: Efficacy and Safety of Confocal Laser Endomicroscopy Guided Medical Thoracoscopy for the Diagnosis of Pleural Disease: a Multicenter Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Pleural Diseases
Pleural Effusion
Lead sponsor: China-Japan Friendship Hospital
Sponsor class: OTHER
First posted: 2024-12-19
Enrollment: 130
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: A prospective multicenter randomized controlled trial was conducted to evaluate the efficacy and safety of thoracoscopic biopsy guided by confocal optical real-time microscopic imaging (nCLE) in the diagnosis of fibrinal pleurisy of unknown etiology. Patients with fibrinous pleurisy of unknown etiology who were to undergo thoracoscopic pleural biopsy were enrolled and informed consent was signed. Subjects were randomized to either the nCLE guided biopsy Group (Group A) or the visual biopsy group (Group B) according to the randomization table (1:1 ratio). nCLE was used to probe the benign and malignant status of pleural lesions, compare the consistency of random pathological biopsy or nCLE guided biopsy with histopathological results, compare whether nCLE guided biopsy can reduce the number of thoracoscopic biopsies, and follow up short-term postoperative complications to evaluate its safety.


Eligibility criteria: Inclusion Criteria:

* Patients with unilateral pleural effusion of unclear aetiology after less invasive means of diagnosis;
* Patients who intend to undergo a thoracoscopic pleural biopsy to determine the cause of pleural effusion;
* Sign informed consent.

Exclusion Criteria:

* There is an uncorrectable coagulation disorder or anticoagulation therapy that cannot be stopped before surgery;
* Hemodynamic instability;
* Refractory hypoxemia;
* Patients with pregnant and lactating patients
* Any illness or condition that interferes with the completion of the initial or subsequent assessment.

Primary outcomes:
measure: The number of biopsies obtained for pathological diagnosis
timeFrame: 12 months
Secondary outcomes:
measure: Incidence of operation-related complications
timeFrame: 7 days
measure: Diagnostic accuracy of pleural diseases
timeFrame: 12 months
measure: time of operation
timeFrame: the day of operation
measure: Overall diagnosis rate of pleural disease
timeFrame: 12 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01657539: Effect of Probiotics Containing Yogurts on the Composition of Biofilms in Patients Under Orthodontic Treatment
Official title: Effects of Yogurt Containing Bifidobacterium Animalis Ssp. Lactis dn- 1173010 Probiotics in the Composition of Biofilms and Saliva of Orthodontic Patients: a Crossover, Double-blind, Randomized and Placebo Controlled Clinical Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Dental Caries
Oral Health
Lead sponsor: Federal University of Pelotas
Sponsor class: OTHER
Collaborators: name: Pontificia Universidade Católica do Rio Grande do Sul
First posted: 2012-08-06
Enrollment: 30
Sex: ALL
Minimum age (years): 14
Maximum age (years): 30
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: Aim: To assess in vivo if the intake of yogurt containing Bifidobacterium animalis ssp. lactis DN- 1173010 probiotic for a period of 2 weeks affects the salivary levels or biofilms of mutans streptococci and the lactobacilli of patients undergoing orthodontic treatment. Methods: A crossover, double-blind, randomized and placebo controlled clinical trial will be performed with 26 volunteers during 4 periods. During periods 2 and 4 (2 weeks each) the volunteers will have a daily ingestion of yogurt containing probiotic or of control yogurt which did not contain probiotic. Periods 1 and 3 were run-in and wash-out periods of 1 and 4 weeks, respectively. Experimental samples of saliva and biofilm will be collected from each participant at the end of each phase. Mutans streptococci, lactobacilli, total aciduric microorganisms, Candida spp. and total cultivable microorganisms will be counted. The values before and after the treatment will be compared with Wilcoxon's test (p\<0.05).


Eligibility criteria: Inclusion Criteria:

* excellent oral health
* patients under bimaxillary orthodontic treatment

Exclusion Criteria:

* any chronic disease
* antibiotics and/or antimicrobial use in the previous 3 weeks
* topic fluoride or chlorhexidine use in the previous 3 weeks
* presence of cavitated or active carious lesions
* patients with intolerance to lactose.

Primary outcomes:
measure: Cariogenic bacteria reduction
timeFrame: 14 days
Secondary outcomes:
measure: Patient discomfort with the treatment
timeFrame: 14 days after intervention
Other outcomes:
Locations:
city: Pelotas
country: Brazil
facility: Graduate Program in Dentistry, Federal University of Pelotas
state: RS
Study officials:
affiliation: Graduate Program in Dentistry, Federal University of Pelotas
name: Maximiliano S Cenci, PhD
role: STUDY_CHAIR
affiliation: Graduate Program in Dentistry, Federal University of Pelotas
name: Gabriela S Pinto, MSc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00178386: Comparison of Educational Services and Outcomes for Patients Treated for Childhood Cancer
Official title: Comparison of Educational Services and Outcomes for Patients Treated for Childhood Cancer and Brain Tumor in Facilities With and Without Educational Liaison Services.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cancer
Brain Tumor
Keywords: cancer
education
learning
brain tumor
school
Lead sponsor: University of Rochester
Sponsor class: OTHER
First posted: 2005-09-15
Enrollment: 220
Sex: ALL
Minimum age (years): 6
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE

Brief summary: The purpose of the study is to evaluate some educational outcomes of children treated for childhood cancer.

Detailed description: The aim of this telephone survey was to test the efficacy of systemic educational program services in improving school outcomes as compared to hospitals who provide educational liaison services in an ad hoc manner.Data from this study will be used to help secure funding to surther investigate the broader use of educational liaison services.

Eligibility criteria: Inclusion Criteria:

* must have had childhood cancer or brain tumor and been diagnosed between 1994-2001 and at least 6 years of age at diagnosis.
* must have been treated at Golisano Children's Hospital or Children's Hospital of Pittsburgh

Exclusion Criteria:

* less than 6 years of age

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: University of Rochester Golisano Children's Hospital
state: New York
city: Pittsburgh
country: United States
facility: Children's Hospital of Pittsburgh
state: Pennsylvania
Study officials:
affiliation: University of Rochester
name: Kathryn Wissler, MS
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Pittsburgh
name: Robert B Noll, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Rochester
name: Olle Jane Z Sahler, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Rochester
name: Georgia Beyer, MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00386139: A Safety and Efficacy Trial of the Combination of Aliskiren / Hydrochlorothiazide (HCTZ)(300/12.5 mg and 300/25 mg) Compared to Aliskiren 300 mg in Hypertensive Patients
Official title: An Eight-week Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / HCTZ (300/12.5 mg and 300/25 mg) in Comparison With Aliskiren 300 mg in Patients With Essential Hypertension Not Adequately Responsive to Aliskiren 300 mg Monotherapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Hypertension
Keywords: Diastolic
systolic
hypertension
aliskiren
blood pressure
hydrochlorothiazide, HCTZ
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2006-10-11
Enrollment: 881
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Evaluate the diastolic blood pressure lowering effect of combination of aliskiren 300 mg and HCTZ (12.5 mg and 25 mg) in hypertensive patients who do not show sufficient blood pressure response to aliskiren 300 mg.


Eligibility criteria: Inclusion Criteria:

* Male or female outpatients 18 years old or older.
* Patients with a diagnosis of hypertension.
* Patients who are eligible and consent to participate in the study

Exclusion Criteria:

* Severe hypertension
* Previous or current diagnosis of heart failure.
* History of hypertensive encephalopathy or cerebrovascular accident, transient ischemic cerebral attack (TIA), myocardial infarction, coronary bypass surgery, or any percutaneous coronary intervention (PCI).
* Other protocol-defined inclusion/exclusion criteria may apply

Primary outcomes:
measure: Mean Sitting Diastolic Blood Pressure lowering effect at baseline, and week 8.
Secondary outcomes:
measure: Mean sitting systolic blood pressure (msDBP) lowering from baseline to week 8
measure: Safety and tolerability
measure: Proportion of patients achieving a blood pressure control target at week 8
Other outcomes:
Locations:
city: East Hanover
country: United States
facility: Novartis Pharmaceuticals
state: New Jersey
city: Investigative Centers
country: Germany
Study officials:
affiliation: Novartis Pharmaceuticals
name: Novartis Pharmaceuticals
role: STUDY_DIRECTOR
References:
citation: Nickenig G, Simanenkov V, Lembo G, Rodriguez P, Salko T, Ritter S, Zhang J. Efficacy of aliskiren/hydrochlorothiazide single-pill combinations in aliskiren non-responders. Blood Press Suppl. 2008 Dec;2:31-40. doi: 10.1080/08038020802507290.
Clinical trial NCT01791439: Glossopharyngeal Nerve Blockade for Awake Videolaryngoscope Assisted Endotracheal Intubation in the Morbidly Obese
Official title: Glossopharyngeal Nerve Blockade for Awake Videolaryngoscope Assisted Endotracheal Intubation in the Morbidly Obese.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Gagging
Lead sponsor: Royal Victoria Hospital, Canada
Sponsor class: OTHER
First posted: 2013-02-15
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The investigators wish to determine if application of 2% lidocaine soaked gauze to the peritonsillar pillars will decrease the amount of gagging caused by awake videolaryngocope assisted tracheal intubation in the morbidly obese.


Eligibility criteria: Inclusion Criteria:

* morbid obese patients scheduled for bariatric surgery, with a planned awake intubation.

Exclusion Criteria:

* inability to communicate in English or french
* allergies to any study drugs
* any patient with an American society of anesthesiologists score of 4 or more

Primary outcomes:
measure: Gagging
timeFrame: 2 minutes
Secondary outcomes:
measure: vital signs
timeFrame: 2 minutes
measure: lidocaine levels
timeFrame: 40 minutes
Other outcomes:
Locations:
city: Montreal
country: Canada
facility: Royal Victoria Hospital
state: Quebec
Study officials:
References:
Clinical trial NCT05995886: Using Facebook to Support Opioid Recovery Among American Indian Women
Official title: Facebook Intervention for Preventing Opioid Relapse Among American Indian Women: Wiidookaage'Win Pilot Preparatory Study (Aim 2)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Opioid Use Disorder
Keywords: American Indian or Alaska Native
Internet-based Intervention
Community-based Participatory Research
Minnesota
Ethnic and Racial Minorities
Women's Health
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
Collaborators: name: National Institute on Drug Abuse (NIDA)
First posted: 2023-08-16
Enrollment: 60
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to find out whether a Facebook group will help Native women in recovery from opioid use.


Eligibility criteria: Inclusion Criteria:

1. AIAN person based on self-reported race/ethnicity
2. Gender identity as a woman
3. At least 18 years of age with no upper age limit
4. Resides in Minnesota
5. Meets criteria for OUD based on the DSM-5 Checklist (American Psychiatric Association, 2013)
6. Self-reports at least one month of abstinence from opioid use based on TLFB interview and negative urine opiate screen
7. Current use of MOUD
8. Is comfortable speaking and reading English
9. Has an existing Facebook account or willing to set one up
10. Is willing and able to participate in the Facebook intervention for 3 months
11. Has access to broadband internet on a mobile phone/computer/tablet at any location
12. Is willing and able to travel to a community clinic in Minneapolis, Minnesota for the UDS or is willing to and able to complete a virtual Zoom UDS visit.
13. Provides written informed consent

Exclusion Criteria:

1. Self-reports current suicidality based on the Concise Heath Risk Tracking scale
2. Participated in prior study phases (Aim 1 formative work) of NIDA CTN-0123

Primary outcomes:
measure: Feasibility of Facebook Intervention
timeFrame: 3 months
Secondary outcomes:
measure: Timeline Follow-back Interview and UDS to measure Opioid Abstinence
timeFrame: 6 months
measure: Reporting MOUD continuation
timeFrame: 6 months
Other outcomes:
measure: Perceived Stress Scale and Communal Mastery Scale
timeFrame: 3 months
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Christi A Patten, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06760286: Breathe-Easy: Food Supplement for Respiratory Health
Official title: Breathe-Easy Study: A Community-Based Trial on the Efficacy of Lung Care Solution for Improving Lung Capacity and Symptom Relief in Respiratory Conditions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Respiration Disorders
Chronic Respiratory Conditions
Pulmonary Diseases or Conditions
Chronic Disease Management
Respiratory Tract Disorders
Keywords: Lung Care
Breathe-Easy
Dietary supplement
Lead sponsor: Innowage Limited
Sponsor class: INDUSTRY
Collaborators: name: Mettle Networks
name: Gyansanjeevani India
First posted: 2025-01-06
Enrollment: 78
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The trial aims to assess the effectiveness of a natural lung care solution and a food supplement in improving lung function, capacity, and alleviating symptoms associated with respiratory conditions like asthma, COPD, and chronic bronchitis.


Eligibility criteria: Inclusion Criteria:

* Adults aged 18 and older.
* Diagnosed with a chronic respiratory condition (e.g., asthma, COPD).
* No known allergies to ingredients in the supplement.
* Ability to provide informed consent and comply with study procedures.

Exclusion Criteria:

* Acute respiratory infection within the last 30 days.
* Current participation in another clinical trial.
* History of severe adverse reactions to similar supplements.

Primary outcomes:
measure: Changes in pulmonary function
timeFrame: Change in forced expiratory volume (FEV1) from baseline to 12 weeks.
Secondary outcomes:
measure: Symptom Severity Scores
timeFrame: Change in symptom scores from baseline to 12 weeks.
measure: Quality of Life (QoL)
timeFrame: Change in quality of life from baseline to 12 weeks.
Other outcomes:
Locations:
city: Jaipur
country: India
facility: Gyansanjeevani India
Study officials:
affiliation: Mettle Networks, UK
name: Sandeep Shinde
role: STUDY_CHAIR
affiliation: Innowage UK
name: Dr Neha Sharma
role: STUDY_DIRECTOR
affiliation: Lexicon MILE, India
name: Dr Bidyanand Jha
role: STUDY_DIRECTOR
affiliation: Gyansanjeevani India
name: Dr Sadhana Sharma
role: PRINCIPAL_INVESTIGATOR
affiliation: Mettle Networks, UK
name: Dr Mridu Sharma
role: STUDY_CHAIR
affiliation: Lexicon MILE, India
name: Dr. Pradyuman S Rathore
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01428739: Correlation Between MRS (Magnetic Resonance Spectroscopy) and Tumor Response to Radiation Therapy in Breast Cancer
Official title: Correlation Between MRS (Magnetic Resonance Spectroscopy) and Tumor Response to Radiation Therapy in Breast Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Breast Cancer
Keywords: cancer
MRS
Treatment response
Lead sponsor: AHS Cancer Control Alberta
Sponsor class: OTHER
First posted: 2011-09-05
Enrollment: 8
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Correlation between MRS and Tumor Response Therapy in Breast Cancer.

Detailed description: Correlation between MRS (Magnetic Resonance Spectroscopy and Tumor Response to Radiation in Breast Cancer

Eligibility criteria: Inclusion Criteria:

* Histologically confirmed diagnosed Breast cancer
* Patient is 18 years or older
* Karnofsky performance score \> 70
* No previously irradiated or recurrent breast cancer
* No contraindication to MRS/MRI
* Signed informed consent.

Primary outcomes:
measure: MRS Correlation with Treatment Response
timeFrame: Up to One Year
Secondary outcomes:
measure: Correlation with Tumor Stage
timeFrame: Up to One year
Other outcomes:
Locations:
city: Edmonton
country: Canada
facility: Cross Cancer Institute
state: Alberta
Study officials:
affiliation: Cross Cancer Institute
name: Nadeem Pervez, MBBS, FFRRCSI, FRCPC
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01010139: Pharmacokinetic and Comparative Bioavailability Study of Codeine Sulfate Under Fasted Conditions
Official title: A Single Dose, 3-Period, 3-Treatment, 6-Sequence Crossover Pharmacokinetic and Comparative Bioavailability Study of Codeine Sulfate Tablet Formulations Under Fasting Conditions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pain
Lead sponsor: West-Ward Pharmaceutical
Sponsor class: INDUSTRY
First posted: 2009-11-09
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The objective of this study designed to characterize the pharmacokinetics and comparative bioavailability of Roxane Laboratories' codeine sulfate tablets after oral administration of 60 mg doses as 1 x 60 mg, 2 x 30 mg and 4 x 15 mg under fasted conditions.


Eligibility criteria: Inclusion Criteria:

* No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening.

Exclusion Criteria:

* Positive test for HIV, Hepatitis B, or Hepatitis C.
* Treatment with known enzyme altering drugs.
* History of allergic or adverse response to codeine sulfate or any comparable or similar product.

Primary outcomes:
measure: bioequivalence determined by statistical comparison Cmax
timeFrame: 21 Days
Secondary outcomes:
Other outcomes:
Locations:
city: San Antonio
country: United States
facility: CEDRA Clinical Research
state: Texas
Study officials:
affiliation: CEDRA Clinical Research
name: James P Doherty, DO
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02080039: Electrical Stimulation of Denervated Muscles After Spinal Cord Injury
Official title: Clinical Pilot Study of the Effect of Electrical Stimulation of Denervated Muscles After Spinal Cord Injury
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Spinal Cord Injury
Keywords: Spinal Cord Injury
Denervation
Electrical Stimulation
Lead sponsor: Swiss Paraplegic Research, Nottwil
Sponsor class: NETWORK
First posted: 2014-03-06
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: In this study the following hypotheses will be tested:

Electrical stimulation of the gluteal muscle (buttocks) leads to

1. an increase in the thickness of the gluteal muscle
2. a decrease in the thickness of the fat of the buttock area
3. a change in the distribution of the middle and maximal seating pressure to a more consistent pressure
4. an increase in well-being of the patients.


Eligibility criteria: Inclusion Criteria:

* Duration of palsy: minimum two years after traumatic or non-traumatic spinal cord injury
* Level of lesion: T 10 to L 5, AIS A, classified by the American Spinal Injury Association (AISA)

Exclusion Criteria:

* Acute decubitus in the stimulated area
* Arteriosclerosis
* Less than three months after flap surgery or after decubitus in the stimulated area
* Infections or skin eczema in the stimulated area

Primary outcomes:
measure: Magnetic Resonance Imaging to determine the thickness of the gluteal muscle and fat tissue of the buttock.
timeFrame: 45 min.
Secondary outcomes:
measure: Measuring of the seating pressure to determine the distribution of the middle and maximal seating pressure
timeFrame: 15 min.
measure: Questionnaire on subjective wellbeing
timeFrame: 10 min.
Other outcomes:
Locations:
city: Nottwil
country: Switzerland
facility: Swiss Paraplegic Centre
state: LU
Study officials:
References:
Clinical trial NCT04451239: Topical Steroids and Cyclosporin-A for COVID-19 Keratoconjunctivitis
Official title: Combined Topical Corticosteroid and Topical Cyclosporine-A for Management of COVID-19 Keratoconjunctivitis; a Pilot Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Keratonjunctivitis
Lead sponsor: Mansoura University
Sponsor class: OTHER
Collaborators: name: Ministry of Health, Kuwait
First posted: 2020-06-30
Enrollment: 12
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To explore the feasibility of combined topical corticosteroid and topical cyclosporine-A in COVID-19 patients with acute keratoconjunctivitis.

Detailed description: COVID-19 patients presenting with acute keratoconjunctivitis will be treated with Topical 1% prednisolone acetate fourTimes daily for 7 days as initial treatment, non-preserved artificial tears four times daily and cyclosporin A 0.5% four times daily .

Twelve patients with COVID-19 Keratoconjunctivitis will be enrolled in this open-label study. Symptoms and findings of the patients before and after treatment were recorded.

Eligibility criteria: Inclusion Criteria:

* COVID-19 Patients with keratoconjunctivitis

Exclusion Criteria:

* associated ocular pathology or disease
* other causes of keratoconjunctivitis for example allergic or herpetic

Primary outcomes:
measure: Symptom improvement
timeFrame: 10-15 days
measure: Signs improvement
timeFrame: 10-15 days
Secondary outcomes:
Other outcomes:
Locations:
city: Kuwait
country: Kuwait
facility: Farawanyia hospital
state: Farawanyia
Study officials:
affiliation: Tanta University
name: Mona Nasseif, MD
role: PRINCIPAL_INVESTIGATOR
References: